Current and novel therapeutic opportunities for systemic therapy in biliary cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-22
DOI
10.1038/s41416-020-0987-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cholangiocarcinoma Disease Modelling Through Patients Derived Organoids
- (2020) Francesco Amato et al. Cells
- Cholangiocarcinoma: Epidemiology and risk factors
- (2019) Shahid A. Khan et al. LIVER INTERNATIONAL
- Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
- (2019) Chiara Braconi et al. LIVER INTERNATIONAL
- Second‐line chemotherapy in biliary tract cancer: Outcome and prognostic factors
- (2019) Nora Schweitzer et al. LIVER INTERNATIONAL
- Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
- (2019) John N Primrose et al. LANCET ONCOLOGY
- Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study
- (2019) Julien Edeline et al. JOURNAL OF CLINICAL ONCOLOGY
- FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.
- (2019) Lipika Goyal et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial.
- (2019) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor
- (2019) Yi Gu et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene Therapy
- (2019) Elisa Lozano et al. HEPATOLOGY
- Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.
- (2019) Milind M. Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.
- (2019) Yung-Jue Bang et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: A phase II trial.
- (2019) Ali Belkouz et al. JOURNAL OF CLINICAL ONCOLOGY
- ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
- (2019) Angela Lamarca et al. JOURNAL OF CLINICAL ONCOLOGY
- FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.
- (2019) David Michael Hyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
- (2019) Jason K. Sicklick et al. NATURE MEDICINE
- TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
- (2019) Lipika Goyal et al. Cancer Discovery
- Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
- (2019) Rachna T. Shroff et al. JAMA Oncology
- Resistance to TRK inhibition mediated by convergent MAPK pathway activation
- (2019) Emiliano Cocco et al. NATURE MEDICINE
- In vitro and molecular chemosensitivity in human cholangiocarcinoma tissues
- (2019) Manida Suksawat et al. PLoS One
- Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
- (2019) C Morizane et al. ANNALS OF ONCOLOGY
- 724PPost-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized phase II study
- (2019) U-F Pape et al. ANNALS OF ONCOLOGY
- LBA10_PRClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
- (2019) G K Abou-Alfa et al. ANNALS OF ONCOLOGY
- LBA40FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
- (2019) A Vogel et al. ANNALS OF ONCOLOGY
- Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study
- (2019) L. Perkhofer et al. BMC CANCER
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Matrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structure
- (2019) Guido Carpino et al. Clinical Proteomics
- Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma
- (2019) Julien Edeline et al. JAMA Oncology
- Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma
- (2019) Andrea Cercek et al. JAMA Oncology
- Current standards and future perspectives in adjuvant treatment for biliary tract cancers
- (2019) Angela Lamarca et al. CANCER TREATMENT REVIEWS
- Modulation of biliary cancer chemo‐resistance through microRNA‐mediated rewiring of the expansion of CD133+ cells
- (2019) Pietro Carotenuto et al. HEPATOLOGY
- O-001Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors
- (2018) F Meric-Bernstam et al. ANNALS OF ONCOLOGY
- Chemoresistance and chemosensitization in cholangiocarcinoma
- (2018) Jose J.G. Marin et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer
- (2018) T. Ebata et al. BRITISH JOURNAL OF SURGERY
- MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma
- (2018) Andrea Lampis et al. GASTROENTEROLOGY
- Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer
- (2018) Masafumi Ikeda et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
- (2018) Hendrik‐Tobias Arkenau et al. ONCOLOGIST
- Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
- (2018) Georgios Vlachogiannis et al. SCIENCE
- HSP90 inhibition drives degradation of FGFR2 fusion proteins: implications for treatment of cholangiocarcinoma
- (2018) Dante Lamberti et al. HEPATOLOGY
- Necroptosis microenvironment directs lineage commitment in liver cancer
- (2018) Marco Seehawer et al. NATURE
- 624PDPreliminary results of a ph2a study to evaluate the clinical efficacy and safety of erdafitinib in Asian patients with biomarker-selected advanced cholangiocarcinoma (CCA)
- (2018) Y-Y Chen et al. ANNALS OF ONCOLOGY
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- (2018) Vincenzo Mazzaferro et al. BRITISH JOURNAL OF CANCER
- Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer
- (2018) Jaihwan Kim et al. PLoS One
- Noncoding RNA in Cholangiocarcinoma
- (2018) Massimiliano Salati et al. SEMINARS IN LIVER DISEASE
- Characterisation of the immune-related transcriptome in resected biliary tract cancers
- (2017) Michele Ghidini et al. EUROPEAN JOURNAL OF CANCER
- Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial
- (2017) Loic Verlingue et al. EUROPEAN JOURNAL OF CANCER
- Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma
- (2017) Massimiliano Cadamuro et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.
- (2017) Milind M. Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy
- (2017) Cristina Quintavalle et al. MOLECULAR CARCINOGENESIS
- miR-106b regulates the 5-fluorouracil resistance by targeting Zbtb7a in cholangiocarcinoma
- (2017) Dechao Jiao et al. Oncotarget
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) J. W. Valle et al. ANNALS OF ONCOLOGY
- Quality of life, long-term survivors and long-term outcome from the ABC-02 study
- (2016) John Bridgewater et al. BRITISH JOURNAL OF CANCER
- ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients
- (2016) Ming-Huang Chen et al. CLINICAL CANCER RESEARCH
- Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
- (2016) Giovanni Brandi et al. ONCOLOGIST
- Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
- (2016) Supriya K. Saha et al. ONCOLOGIST
- Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues
- (2015) Bertrand Brieau et al. CANCER
- Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma
- (2015) Ju Dong Yang et al. HEPATOLOGY
- Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness
- (2015) WAREEPORN WATTANAWONGDON et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Genomic spectra of biliary tract cancer
- (2015) Hiromi Nakamura et al. NATURE GENETICS
- Second-line chemotherapy in advanced biliary cancer: a systematic review
- (2014) A. Lamarca et al. ANNALS OF ONCOLOGY
- Activating Mutations in PTPN3 Promote Cholangiocarcinoma Cell Proliferation and Migration and Are Associated With Tumor Recurrence in Patients
- (2014) Qiang Gao et al. GASTROENTEROLOGY
- XIAP Antagonist Embelin Inhibited Proliferation of Cholangiocarcinoma Cells
- (2014) Cody J. Wehrkamp et al. PLoS One
- Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis
- (2013) F Peng et al. BRITISH JOURNAL OF CANCER
- Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial–mesenchymal transition and chemoresistance in biliary tract cancer
- (2013) Daisaku Yamada et al. EUROPEAN JOURNAL OF CANCER
- Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
- (2013) Daniela Sia et al. GASTROENTEROLOGY
- Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targeting
- (2013) Alphonse E. Sirica et al. HEPATOLOGY
- NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway
- (2013) XIANXIU GE et al. ONCOLOGY REPORTS
- miR-29b, miR-205 and miR-221 Enhance Chemosensitivity to Gemcitabine in HuH28 Human Cholangiocarcinoma Cells
- (2013) Kinya Okamoto et al. PLoS One
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers
- (2013) Yi-Mi Wu et al. Cancer Discovery
- Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma
- (2012) J. C. Mertens et al. CANCER RESEARCH
- Outcome of second-line chemotherapy for biliary tract cancer
- (2012) John Bridgewater et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
- (2012) Anne M. Horgan et al. JOURNAL OF CLINICAL ONCOLOGY
- No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors
- (2012) P. Martinez-Becerra et al. MOLECULAR PHARMACEUTICS
- What are regulatory T cells (Treg) regulating in cancer and why?
- (2012) Theresa L. Whiteside SEMINARS IN CANCER BIOLOGY
- Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil
- (2012) Chariya Hahnvajanawong WORLD JOURNAL OF GASTROENTEROLOGY
- Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma
- (2011) Jun Sato et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2
- (2010) Hyunho Yoon et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
- (2010) T Okusaka et al. BRITISH JOURNAL OF CANCER
- Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy
- (2010) Zichen Zhang et al. HEPATOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biogenesis of small RNAs in animals
- (2009) V. Narry Kim et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma
- (2008) Lei Chen et al. JOURNAL OF HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started